1-4 of 4
Weishi Yuan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA's Approval of the First Biosimilar to Bevacizumab

Free
Sandra J. Casak, Steven J. Lemery, Jee Chung, Chana Fuchs, Sarah J. Schrieber, Edwin C.Y. Chow, Weishi Yuan, Lisa Rodriguez, Thomas Gwise, Anne Rowzee, Sue Lim, Patricia Keegan, Amy E. McKee, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4365–4370.
https://doi.org/10.1158/1078-0432.CCR-18-0566
Published: 14 September 2018
View articletitled, FDA's Approval of the First Biosimilar to Bevacizumab
Open the PDF for FDA's Approval of the First Biosimilar to Bevacizumab in another window
Journal Articles

FDA Approval Summary: TAS-102

Free
Leigh Marcus, Steven J. Lemery, Sachia Khasar, Emily Wearne, Whitney S. Helms, Weishi Yuan, Kun He, Xianhua Cao, Jingyu Yu, Hong Zhao, Yaning Wang, Olen Stephens, Erika Englund, Rajiv Agarwal, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 2924–2927.
https://doi.org/10.1158/1078-0432.CCR-16-2157
Published: 14 June 2017
View articletitled, FDA Approval Summary: TAS-102
Open the PDF for FDA Approval Summary: TAS-102 in another window
Journal Articles

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer

Free
Dickran Kazandjian, Gideon M. Blumenthal, Weishi Yuan, Kun He, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1307–1312.
https://doi.org/10.1158/1078-0432.CCR-15-2266
Published: 14 March 2016
View articletitled, FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer
Open the PDF for FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer in another window
Journal Articles

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial

Free
Martha Donoghue, Steven J. Lemery, Weishi Yuan, Kun He, Rajeshwari Sridhara, Stacy Shord, Hong Zhao, Anshu Marathe, Lori Kotch, Josephine Jee, Ying Wang, Liang Zhou, William M. Adams, Vaishali Jarral, Anne Pilaro, Richard Lostritto, Joseph E. Gootenberg, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1496–1505.
https://doi.org/10.1158/1078-0432.CCR-11-2149
Published: 14 March 2012
View articletitled, Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial
Open the PDF for Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial in another window